Treats head lice infestations. Sold as Natroba. Every FDA application for this active ingredient.
As of Nov 14, 2026, FDA lists 1 application for Spinosad (sold as Natroba), first approved Jan 18, 2011, with 2 new uses approved and 0 published complete response letters.
| Spinosad | Part D | $446K | +17% | 1,350 |
| Natroba | Part D | $245K | +52% | 659 |
| Comparison of Topical Permethrin 5% and Spinosad 0.9% for Scabies TreatmentScabies · University of Faisalabad | Not applicable | Not yet recruiting | Nov 13, 2026 |
| A Phase 2 Study to Compare Efficacy and Safety of a Novel Topical Therapy (APT-001, Spinosad 1.8%) in Patients With BlepharitisBlepharitis · Aperta Biosciences, LLC | Phase 2 | Not yet recruiting | Oct 29, 2026 |
Applications, approvals and products come from FDA's Drugs@FDA data files, refreshed weekly, grouped by active ingredient as FDA spells it. Complete response letters are FDA's published letters. Medicare spending is CMS's Part D and Part B dashboard, matched to this ingredient by generic name; shortages are FDA's shortage list, matched by application number; clinical trials are ClinicalTrials.gov studies naming the ingredient as an intervention, refreshed daily; safety programs are FDA's REMS list, matched by application number or, for shared programs, by ingredient. Drugs@FDA
